These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38878765)

  • 1. Immunotherapy in locally advanced cervical cancer: Integrating KEYNOTE-A18 into management strategies.
    How JA; Jazaeri AA
    Med; 2024 Jun; 5(6):487-489. PubMed ID: 38878765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacotherapy for cervical cancer: current standard of care and new perspectives.
    Ketch PW; Zaharias RS; Leath CA
    Expert Opin Pharmacother; 2024 Aug; 25(12):1591-1603. PubMed ID: 39164924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of chemoradiotherapy plus immune checkpoint inhibitors for the treatment of locally advanced cervical cancer: a systematic review and meta-analysis.
    Zhao Z; Ruan J; Fang M; Liu J; Liao G
    Front Immunol; 2024; 15():1459693. PubMed ID: 39351236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regarding "Immunotherapy in locally advanced cervix cancer: A critical appraisal of the FDA indication based on ENGOT-CX11/GOG-3047/KEYNOTE-A18".
    da Costa AABA; Souza RP; Pandolfi NC; de Souza Castro F; Baiocchi G; Guimarães APG
    Gynecol Oncol; 2024 Oct; 189():109-110. PubMed ID: 39084160
    [No Abstract]   [Full Text] [Related]  

  • 5. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.
    Lorusso D; Xiang Y; Hasegawa K; Scambia G; Leiva M; Ramos-Elias P; Acevedo A; Sukhin V; Cloven N; Pereira de Santana Gomes AJ; Contreras Mejía F; Reiss A; Ayhan A; Lee JY; Saevets V; Zagouri F; Gilbert L; Sehouli J; Tharavichitkul E; Lindemann K; Lazzari R; Chang CL; Lampé R; Zhu H; Oaknin A; Christiaens M; Polterauer S; Usami T; Li K; Yamada K; Toker S; Keefe SM; Pignata S; Duska LR;
    Lancet; 2024 Apr; 403(10434):1341-1350. PubMed ID: 38521086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of an early safety analysis of a study of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer.
    Duska LR; Scalici JM; Temkin SM; Schwarz JK; Crane EK; Moxley KM; Hamilton CA; Wethington SL; Petroni GR; Varhegyi NE; Clift SH; Bullock TNJ; Showalter TN
    Cancer; 2020 Nov; 126(22):4948-4956. PubMed ID: 32910478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy in locally advanced cervix cancer: A critical appraisal of the FDA indication based on ENGOT-CX11/GOG-3047/KEYNOTE-A18.
    Monk BJ; Tewari KS; Randall LM; Pothuri B; Slomovitz BM; Coleman RL; Herzog TJ
    Gynecol Oncol; 2024 Sep; 188():81-82. PubMed ID: 38936284
    [No Abstract]   [Full Text] [Related]  

  • 8. Pembrolizumab for advanced cervical cancer: safety and efficacy.
    De Felice F; Giudice E; Bolomini G; Distefano MG; Scambia G; Fagotti A; Marchetti C
    Expert Rev Anticancer Ther; 2021 Feb; 21(2):221-228. PubMed ID: 33183120
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunotherapy for Uterine Cervical Cancer Using Checkpoint Inhibitors: Future Directions.
    Kagabu M; Nagasawa T; Sato C; Fukagawa Y; Kawamura H; Tomabechi H; Takemoto S; Shoji T; Baba T
    Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32230938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of nimotuzumab in combination with immunotherapy for a young recurrent cervical cancer patient: a case report and literature review.
    Shi M; Zhang Y
    Anticancer Drugs; 2024 Aug; 35(7):644-652. PubMed ID: 38950136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pembrolizumab plus chemoradiotherapy effective in locally advanced cervical cancer.
    Sidaway P
    Nat Rev Clin Oncol; 2024 Jun; 21(6):402. PubMed ID: 38565936
    [No Abstract]   [Full Text] [Related]  

  • 12. Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update.
    Verhoeven Y; Quatannens D; Trinh XB; Wouters A; Smits ELJ; Lardon F; De Waele J; van Dam PA
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toripalimab combined with concurrent platinum-based Chemoradiotherapy in patients with locally advanced cervical Cancer: an open-label, single-arm, phase II trial.
    Chen J; Li C; Cao Y; Zhu L; Zhang B; You J; Hou H; Wang J; Yuan Z
    BMC Cancer; 2022 Jul; 22(1):793. PubMed ID: 35854236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of pembrolizumab for treatment of US patients with persistent, recurrent, or metastatic cervical cancer.
    Shi Y; Chen J; Shi B; Liu A
    Gynecol Oncol; 2022 Feb; 164(2):379-385. PubMed ID: 34920886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412.
    Machiels JP; Tao Y; Burtness B; Tahara M; Licitra L; Rischin D; Waldron J; Simon C; Gregoire V; Harrington K; Alves GV; Figueiredo Lima IP; Pointreau Y; M Hughes BG; Aksoy S; Hetnal M; Ge JY; Brown H; Cheng J; Bidadi B; Siu LL
    Future Oncol; 2020 Jun; 16(18):1235-1243. PubMed ID: 32490686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Balstilimab and other immunotherapy for recurrent and metastatic cervical cancer.
    Bose CK
    Med Oncol; 2022 Jan; 39(4):47. PubMed ID: 35092506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer.
    Kehl KL; Greenwald S; Chamoun NG; Manberg PJ; Schrag D
    JAMA Netw Open; 2021 May; 4(5):e2111113. PubMed ID: 34019086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Who should be treated with pembrolizumab in addition to standard of care in advanced cervical cancer?
    Kahraman S; Erbas UE; Yalcin B
    Med Oncol; 2022 Jan; 39(3):33. PubMed ID: 35059847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant chemotherapy after concurrent chemoradiation for locally advanced cervical cancer.
    Tangjitgamol S; Katanyoo K; Laopaiboon M; Lumbiganon P; Manusirivithaya S; Supawattanabodee B
    Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD010401. PubMed ID: 25470408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing immunotherapy for gynecologic cancers.
    Rubinstein MM; Makker V
    Curr Opin Obstet Gynecol; 2020 Feb; 32(1):1-8. PubMed ID: 31833942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.